Julie Kim is president of the U.S. Business Unit, U.S. country head and member of Takeda’s Executive Team. The U.S. Business Unit portfolio encompasses gastroenterology, neuroscience, plasma-derived therapies and rare diseases.

1 day ago · CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process

1 day ago · Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor ...

CEO Christophe Weber to retire from Takeda in June 2026 after 12 yearsJulie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process Takeda(TOKYO:4502/NYSE:TAK) announced today that itsBoard of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the …

1 day ago · Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as the drugmaker’s new chief executive officer.

1 day ago · Takeda (TOKYO:4502/NYSE:TAK) has announced that Julie Kim, current president of Takeda's U.S. Business Unit, will succeed Christophe Weber as CEO when he retires in June 2026. The decision was made unanimously by the Board of Directors after a multi-year succession process evaluating both internal and external candidates.Weber, who joined …

President, U.S. Business Unit at Takeda · My journey in the healthcare industry has been driven by a singular vision—championing innovative treatments and access to the best care possible, while...

Julie Kim is President of the U.S. Business Unit, U.S. Country Head and member of Takeda’s Executive Team. The U.S. Business Unit portfolio encompasses gastroenterology, neuroscience, plasma-derived therapies and rare diseases.

1 day ago · ジュリー・キムが2026年6月にクリストフ・ウェバーの後任として就任 2025年1月30日 Share

Julie Kim is the president of Takeda’s U.S. Business Unit, U.S. Country Head, and a member of the company’s Executive Team. She oversees a diverse portfolio that includes gastroenterology, neuroscience, plasma-derived therapies, and rare diseases.